Home Newsfeeds Keybanc Initiates Coverage On PDC Energy with Sector Weight Rating

Keybanc Initiates Coverage On PDC Energy with Sector Weight Rating

Keybanc analyst Tim Rezvan initiates coverage on PDC Energy (NASDAQ:PDCE) with a Sector Weight rating.

byBenzinga Newsdesk

September 20, 2022

1 minute read

Keybanc analyst Tim Rezvan initiates coverage on PDC Energy (NASDAQ:PDCE) with a Sector Weight rating.

Delta Air Lines Analysts Boost Their Forecasts After Upbeat Q2 Results

By Lisa Levin

July 14, 11:34 AM

Delta Air Lines Inc (NYSE: DAL) reported better-than-expected second-quarter results.

DAL

Baxter Signs Definitive Agreement To Divest Its BioPharma Solutions Business To Advent International And Warburg Pincus For $4.25B

By Happy Mohamed

May 8, 9:59 AM

Proposed divestiture of BioPharma Solutions (BPS) further streamlines Baxter's strategic focus and represents an important milestone in its ongoing business transformation Net proceeds planned to be redeployed for

BAX

Piper Sandler Maintains Overweight on Revance Therapeutics, Raises Price Target to $40

By Benzinga Newsdesk

January 31, 7:24 AM

Piper Sandler analyst David Amsellem maintains Revance Therapeutics (NASDAQ:RVNC) with a Overweight and raises the price target from $29 to $40.

RVNC

S&P 500 Settles Higher; Market Volatility Increases Further

By Lisa Levin

May 16, 5:39 AM

The S&P 500 settled higher on Monday amid optimism that the debt ceiling talks scheduled on Tuesday could yield some results. Investors also assessed the economic data released Monday, which showed the NY Empire State Manufacturing Index falling to -31.8 in May from 10.8 in the previous month, versus analysts’ estimates of -3.75.

AMZN

Keybanc Initiates Coverage On PDC Energy with Sector Weight Rating

Related Posts

Delta Air Lines Analysts Boost Their Forecasts After Upbeat Q2 Results

Baxter Signs Definitive Agreement To Divest Its BioPharma Solutions Business To Advent International And Warburg Pincus For $4.25B

Piper Sandler Maintains Overweight on Revance Therapeutics, Raises Price Target to $40

S&P 500 Settles Higher; Market Volatility Increases Further